Join Penn Medicine's Abramson Cancer Center and 6ABC for a special one-hour live web chat featuring physicians from the Penn Mesothelioma and Pleural Program this Thursday May 1st from 4-5 pm at 6abc.com/pennmedicine.
Mesothelioma - Did you know?
Mesothelioma is a rare, incurable disease, with approximately 2,000–3,000 new cases diagnosed a year in the United States. Exposure to asbestos accounts for up to 80% of all cases. Mesothelioma is more common in men mostly due to occupational exposure to asbestos.
Veterans, miners, factory workers, and those working in the manufacturing or construction business are at a greater risk of developing mesothelioma due to asbestos exposure.
Mesothelioma Can Be Treated
A popular misconception is that mesothelioma is a disease that can't be treated. Due to the complexity of this incurable disease, a true multidisciplinary approach is needed to ensure the best care available.
The Penn Mesothelioma and Pleural Program team has expertise in all types of treatment, including Lung-Sparing Surgery and Photodynamic Therapy, Immunotherapy, Proton Therapy, Radiation Therapy and Chemotherapy.
It is hard to find a group with the subspecialized experience as the team at Penn Medicine. Patients benefit from Penn Medicine's ongoing research and our passion to eradicate this disease while providing the highest possible quality of life for each patient and their families as well.
Our Experts Answering Your Questions
Want to know more about:
- Mesothelioma symptoms?
- Is Screening available?
- Penn Medicine's multidisciplinary approach?
- Cutting edge treatment options?
- New breakthrough clinical trials?
- How to improve quality of life after diagnosis?
The Penn Medicine Mesothelioma and Pleural Program brings together internationally renowned experts. Representing the full spectrum of the Penn Mesothelioma and Pleural Program are director Joseph S. Friedberg, MD, Chief of the Division of Thoracic Surgery and co-director Daniel Sterman, MD, Director of Interventional Pulmonary Services, Evan W. Alley, MD, PhD Interim Chief of the Division of Hematology and Medical Oncology Hematology-Oncology and Charles B. Simone, MD an Assistant Professor of Radiation Oncology at the Hospital of the University of Pennsylvania.
These Penn Medicine experts will be answering user-submitted questions in a live online chat next Thursday May 1st, from 4 - 5pm.